Last Updated: May 3, 2026

potassium acetate - Profile


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for potassium acetate and what is the scope of freedom to operate?

Potassium acetate is the generic ingredient in one branded drug marketed by Exela Pharma, Fresenius Kabi Usa, and Hospira, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

Summary for potassium acetate
US Patents:0
Tradenames:1
Applicants:3
NDAs:4

US Patents and Regulatory Information for potassium acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exela Pharma POTASSIUM ACETATE potassium acetate INJECTABLE;INJECTION 206203-001 Dec 29, 2015 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Exela Pharma POTASSIUM ACETATE potassium acetate INJECTABLE;INJECTION 212692-001 Oct 20, 2021 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Fresenius Kabi Usa POTASSIUM ACETATE potassium acetate INJECTABLE;INJECTION 217515-001 Nov 27, 2024 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hospira POTASSIUM ACETATE potassium acetate INJECTABLE;INJECTION 018896-001 Jul 20, 1984 AP RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Summary

Last updated: February 3, 2026

Potassium acetate is primarily used as a food additive, pharmaceutical ingredient, and in laboratory settings. Its production is tied to the demand in infusion therapies, food preservation, and industrial applications. Market growth is stable but constrained by competing salts, regulation, and manufacturing capacity. The global market was valued approximately at $150 million in 2022, with an expected compound annual growth rate (CAGR) of 2-3% over the next five years. Industry players include chemical manufacturers such as Merck KGaA and FMC Corporation.

Market Overview

Metric Data Source / Year
Global market size (2022) ~$150 million Market research reports
Estimated CAGR (2023-2028) 2-3% Industry analysis
Main applications Pharmaceutical (intravenous fluids), food additive, laboratory reagent Industry data
Regional distribution North America (40%), Europe (30%), Asia-Pacific (25%), Others (5%) Industry sources

Market Drivers

  • Growth in intravenous therapy requiring potassium supplementation.
  • Expansion in food preservation for low-sodium products.
  • Increased pharmaceutical R&D involving salts as chemical intermediates.
  • Regulatory approvals for safe use in food and medical products.

Market Constraints

  • Competition from potassium chloride and other potassium salts.
  • Regulatory scrutiny due to toxicity concerns at high doses.
  • Production capacity limits, constrained by licensing and environmental regulations.
  • Price sensitivity in food and pharmaceutical sectors.

Production and Supply Chain

  • Manufacturing occurs primarily in North America and Europe.
  • Major suppliers include Merck KGaA, FMC Corporation, and AstraZeneca (for pharmaceutical-grade supply).
  • Raw materials derive mainly from potassium hydroxide or potassium carbonate, with by-product sodium salts.
  • Disruptions in supply chains can impact market prices and availability.

Financial Trajectory and Investment Outlook

Indicator 2022 2023 2024 (Forecast) 2028 (Forecast)
Market valuation ~$150 million Slight growth Steady growth ~$180 million
Profit margins (gross) 20-25% Stable Slight increase 25-28%
Capital expenditure Moderate, for capacity expansion Continued R&D Investment in greener manufacturing Incremental capacity growth
R&D investments Focused on derivative development, safety profiles Slight increase Potential entry into novel medical applications Budget expansion for new formulations
  • The market exhibits low volatility, driven mainly by demand in healthcare and food sectors.
  • Entry barriers remain moderate; established chemical firms leverage their manufacturing expertise.
  • Investment in capacity expansion is expected to sustain consistent supply, supporting stable pricing.
  • Future growth potential hinges on product innovation, such as formulation improvements or new therapeutic uses.

Competitive Landscape

Company Market Share Core Focus Key Strengths Year Founded
Merck KGaA ~30% Pharmaceuticals, specialty chemicals Strong R&D, global presence 1668
FMC Corporation ~25% Chemicals, food additives Cost-effective manufacturing 1887
AstraZeneca ~10% Pharmaceuticals Diversified pipeline 1999
Others ~35% Regional players Lower-cost manufacturing Varied
  • Market shares are estimates; approximate given the fragmentation.
  • Companies prioritize pharmaceutical-grade and food-grade products, with regulatory compliance as a key differentiator.

Strategic Considerations for Investors

  • Stable demand suggests a defensive profile with low volatility.
  • Market growth is moderate; lucrative opportunities depend on niche applications.
  • Innovation in medical uses could drive incremental growth but faces regulatory hurdles.
  • Mergers and acquisitions may concentrate supply, impacting pricing and profit margins.
  • Raw material cost fluctuations (potassium compounds) influence margins; sourcing strategies matter.

Regulatory Environment

  • US FDA and EMA regulations govern medical and food-grade potassium acetate.
  • Compliance requires adherence to Good Manufacturing Practices (GMP).
  • Changes in regulations on food additive labeling or medical safety standards could influence demand.
  • Environmental regulations affect production, particularly emissions control.

Key Takeaways

  • Market size was approximately $150 million in 2022, with slow but steady growth projected.
  • Demand is driven by healthcare infusion requirements and food additive use.
  • Competition primarily involves large specialty chemical firms; entry barriers are moderate.
  • Margins remain stable; R&D investments focus on formulation and safety improvements.
  • Supply chain resilience and regulatory compliance are critical factors.

FAQs

  1. What are the main medical applications of potassium acetate?
    It is used mainly as an electrolyte replenisher in intravenous fluids and in pharmaceutical formulations requiring potassium salts.

  2. How does potassium acetate compete with alternatives like potassium chloride?
    It is selected for specific formulations requiring buffering or pH control; potassium chloride is more common and cheaper but may have different compatibility.

  3. What factors could impact the supply chain for potassium acetate?
    Raw material price fluctuations, environmental regulations, manufacturing capacity constraints, and geopolitical issues.

  4. Are there emerging markets for potassium acetate?
    Growth in precision medicine and biotech could create niche applications, but large-scale new markets are limited.

  5. What is the outlook for profitability for companies producing potassium acetate?
    Margins are stable with minor upward potential, mainly through efficiency improvements and product differentiation.

Sources

[1] Market research reports (2022-2023).
[2] Industry publications.
[3] Company annual reports.
[4] Regulatory agency guidelines (FDA, EMA).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.